Most S&P 500 healthcare stocks deliver earnings beat this week

21 out of 60 S&P 500 health care companies reported quarterly results this week, of which 20 delivered an earnings beat, and one came in-line with estimates.

16 of the reporting companies exceeded revenue consensus, while five trailed expectation.

Below are the latest quarterly reports from top health care companies this week:

Pfizer (PFE [https://seekingalpha.com/symbol/PFE]) exceeded Street forecasts [https://seekingalpha.com/news/4514072-pfizer-raises-earnings-outlook-q3-beat] with its Q3 results, thanks mainly to sales from its COVID vaccine. The company raised its full-year earnings outlook while reaffirming the revenue guidance. [https://seekingalpha.com/news/4514069-pfizer-non-gaap-eps-of-0_87-beats-by-0_23-revenue-of-16_65b-beats-by-150m]

Moderna (MRNA [https://seekingalpha.com/symbol/MRNA]) reported Q3 results [https://seekingalpha.com/news/4517199-moderna-stock-gains-after-q3-2025-beat] beat, even as its topline continued to contract sharply amid declining COVID vaccine sales. [https://seekingalpha.com/news/4517152-moderna-gaap-eps-of-0_51-beats-by-1_67-revenue-of-1_02b-beats-by-150_11m]

Xanax maker Viatris (VTRS [https://seekingalpha.com/symbol/VTRS]) beat Wall Street forecasts [https://seekingalpha.com/news/4517286-viatris-raises-2025-outlook-q3-beat] with its Q3 2025 financials thanks mainly to growth in emerging markets, and the company raised its full-year outlook in line with the consensus.

Amgen (AMGN [https://seekingalpha.com/symbol/AMGN]) easily beat [https://seekingalpha.com/news/4515077-amgen-q3-beats-both-lines-adjusts-2025-guidance-ranges-revenue-eps] estimates [https://seekingalpha.com/news/4515077-amgen-q3-beats-both-lines-adjusts-2025-guidance-ranges-revenue-eps] on both lines in its Q3 financial results driven by double-digit year-over-year increases in some of its top-selling drugs.

QTD, 57 out of the 60 energy companies have reported earnings so far, with 55 delivering an earnings beat.

For the week, the Health Care Select Sector SPDR Fund ETF (XLV [https://seekingalpha.com/symbol/XLV]) added 1.2%, while the broader SPDR S&P 500 ETF Trust (SPY [https://seekingalpha.com/symbol/SPY]) lost 1.8%.

Related ETFs: Health Care Select Sector SPDR Fund (NYSEARCA:XLV [https://seekingalpha.com/symbol/XLV#hasComeFromMpArticle=false#source=section%3Amain_content%7Cbutton%3Abody_link%7Cfirst_level_url%3Anews]), SPDR S&P Pharmaceuticals ETF (NYSEARCA:XPH [https://seekingalpha.com/symbol/XPH#hasComeFromMpArticle=false#source=section%3Amain_content%7Cbutton%3Abody_link%7Cfirst_level_url%3Anews]), VanEck Pharmaceutical ETF (NASDAQ:PPH [https://seekingalpha.com/symbol/PPH#hasComeFromMpArticle=false#source=section%3Amain_content%7Cbutton%3Abody_link%7Cfirst_level_url%3Anews]), iShares Nasdaq Biotechnology ETF (NASDAQ:IBB [https://seekingalpha.com/symbol/IBB#hasComeFromMpArticle=false#source=section%3Amain_content%7Cbutton%3Abody_link%7Cfirst_level_url%3Anews]), iShares U.S. Pharmaceuticals ETF (NYSEARCA:IHE [https://seekingalpha.com/symbol/IHE#hasComeFromMpArticle=false#source=section%3Amain_content%7Cbutton%3Abody_link%7Cfirst_level_url%3Anews]), and Invesco Nasdaq Biotechnology ETF (NASDAQ:IBBQ [https://seekingalpha.com/symbol/IBBQ#hasComeFromMpArticle=false#source=section%3Amain_content%7Cbutton%3Abody_link%7Cfirst_level_url%3Anews]).

MORE ON THE HEALTH CARE SELECT SECTOR SPDR® FUND ETF

* XLV: Lower Interest Rates And A Positive Growth Outlook Will Pave The Way [https://seekingalpha.com/article/4830912-xlv-lower-interest-rates-and-a-positive-growth-outlook-will-pave-the-way]
* XLV: Market Overreaction Could Drive Double Digit Shareholder Yield [https://seekingalpha.com/article/4822422-xlv-market-overreaction-could-drive-double-digit-shareholder-yield]
* XLV Vs. IHE: Will Pharmaceuticals Outperform Healthcare? [https://seekingalpha.com/article/4817656-xlv-vs-ihe-will-pharmaceuticals-outperform-healthcare]
* Bitcoin nears bear market territory as $100K level comes under pressure [https://seekingalpha.com/news/4515670-bitcoin-nears-bear-market-territory-as-100k-level-comes-under-pressure]
* Notable healthcare headlines for the week: UNH, Eli Lilly and Merck in focus [https://seekingalpha.com/news/4512600-notable-healthcare-headlines-for-the-week-unh-eli-lilly-and-merck-in-focus]